Scynexis (SCYX) Gains from Investment Securities (2013 - 2026)
Scynexis (SCYX) posted Gains from Investment Securities of $5.2 million for Q1 2026, up 512.33% on a QoQ basis from -$1.3 million in Q4 2025, and up 279.27% year-over-year from $1.4 million in Q1 2025.
Scynexis (SCYX) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Scynexis' Gains from Investment Securities history runs 13 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- Quarterly Gains from Investment Securities rose 279.27% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 134.12% YoY) and the FY2025 annual result came in at -$5.8 million, up 58.2% from the prior year.
- Gains from Investment Securities was $5.2 million for Q1 2026 at Scynexis, up from -$1.3 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $21.7 million in Q3 2022 and bottomed at -$10.0 million in Q1 2022.
- A 5-year average of -$1.1 million and a median of -$2.9 million in 2025 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities plunged 673.92% — and 2023, when it jumped 316.08%.
- Scynexis' Gains from Investment Securities stood at -$9.1 million in 2022, then soared by 69.18% to -$2.8 million in 2023, then declined by 14.79% to -$3.2 million in 2024, then jumped by 60.39% to -$1.3 million in 2025, then jumped by 512.33% to $5.2 million in 2026.
- Business Quant data shows SCYX's Gains from Investment Securities at $5.2 million in Q1 2026, -$1.3 million in Q4 2025, and $640000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Scynexis | 23.19 Mn | -13.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.25 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | -1.27 Mn |
| Dec 31, 2025 | -1.27 Mn |
| Sep 30, 2025 | 640,000.00 |
| Sep 30, 2025 | 640,000.00 |
| Jun 30, 2025 | -2.17 Mn |
| Jun 30, 2025 | -2.17 Mn |
| Mar 31, 2025 | -2.93 Mn |
| Mar 31, 2025 | -2.93 Mn |
| Dec 31, 2024 | -3.21 Mn |
| Dec 31, 2024 | -3.21 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Dec 31, 2023 | -2.80 Mn |
| Dec 31, 2023 | -2.80 Mn |